Related coverage linked through entity extraction aliases.
May 16, 2026
The TGA warned about the risk of homicidal ideation associated with atomoxetine in paediatric patients and published its February 2026 Product Information safety updates. The updates cover multiple medicines with changes to contraindications, warnings and adverse effects. Nearly one in five Australians took a prescription psychiatric drug in 2023-24.
May 11, 2026
Tracy Beth Høeg said in her first address to staff that she will scrutinize antidepressants and RSV products used to protect babies. She said she is prioritizing the health of women and babies.
Mar 25, 2026
Clinical trials show psychedelic substances like psilocybin, LSD and MDMA combined with therapy can effectively treat depression, anxiety and addiction. Several substances are in Phase III trials, with esketamine already approved for treatment-resistant depression. Research suggests these treatments may work with fewer doses than traditional medications.
Feb 27, 2026
Compass Pathways announced successful Phase 3 trial results for COMP360, a synthetic psilocybin treatment for treatment-resistant depression, showing rapid onset and durable effects with a 40% response rate after two doses.
Feb 14, 2026
A population-based study of over 1.27 million births found SSRI antidepressants during pregnancy increase gestational diabetes risk but reduce preterm birth and low birth weight risks, with effects independent of maternal depression.
